{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:07:01Z","timestamp":1787022421063,"version":"build-2736575974"},"reference-count":38,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0765","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T18:07:13Z","timestamp":1617818833000},"page":"905-918","source":"Crossref","is-referenced-by-count":6,"title":["Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA\u2013LONG TERM)"],"prefix":"10.1507","volume":"68","author":[{"given":"Kazuyuki","family":"Tobe","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maegawa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science, Shiga, 520-2192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Operational Excellence, Medical Affairs Japan, Astellas Pharma Inc., Tokyo, 103-8411, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uno","sequence":"additional","affiliation":[{"name":"Data Science, Development, Astellas Pharma Inc., Tokyo, 103-8411, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Poole RM, Dungo RT (2014) Ipragliflozin: first global approval. Drugs 74: 611\u2013617.","DOI":"10.1007\/s40265-014-0204-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Watada H (2020) Current understanding of the effect of sodium\u2013glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus. Diabetol Int 11: 242\u2013244.","DOI":"10.1007\/s13340-020-00443-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kitada M, Hirai T, Koya D (2020) Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetol Int 11: 245\u2013251.","DOI":"10.1007\/s13340-020-00444-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Tanaka A, Node K (2020) Promising roles of sodium\u2013glucose cotransporter 2 inhibitors in heart failure prevention and treatment. Diabetol Int 11: 252\u2013260.","DOI":"10.1007\/s13340-020-00445-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Araki E, Goto A, Kondo T, Noda M, Noto H, et al. (2020) Japanese clinical practice guideline for diabetes 2019. Diabetol Int 11: 165\u2013223.","DOI":"10.1007\/s13340-020-00439-5"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6 El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460\u2013468.","DOI":"10.1053\/j.gastro.2003.10.065"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, et al. (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71: 793\u2013801.","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Okanoue T, Umemura A, Yasui K, Itoh Y (2011) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol 26 Suppl 1: 153\u2013162.","DOI":"10.1111\/j.1440-1746.2010.06547.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69: 896\u2013904.","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"10","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","volume":"30","author":"G Targher","year":"2007","unstructured":"10 Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212\u20131218.","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, et al. (2010) Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105: 1567\u20131573.","DOI":"10.1038\/ajg.2010.18"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, et al. (2015) Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754: 19\u201324.","DOI":"10.1016\/j.ejphar.2015.02.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, et al. (2016) The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 11: e0146337.","DOI":"10.1371\/journal.pone.0146337"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715: 246\u2013255.","DOI":"10.1016\/j.ejphar.2013.05.014"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tahara A, Takasu T (2019) SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Physiol Rep 7: e14286.","DOI":"10.14814\/phy2.14286"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tahara A, Takasu T (2020) Therapeutic effects of SGLT2 inhibitor ipragliflozin and metformin on NASH in type 2 diabetic mice. Endocr Res 45: 147\u2013161.","DOI":"10.1080\/07435800.2020.1713802"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, et al. (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11: e0151511.","DOI":"10.1371\/journal.pone.0151511"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ohta A, Kato H, Ishii S, Sasaki Y, Nakamura Y, et al. (2017) Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother 18: 1433\u20131438.","DOI":"10.1080\/14656566.2017.1363888"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T (2017) Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J 64: 363\u2013367.","DOI":"10.1507\/endocrj.EJ16-0295"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yamauchi Y, Nakamura A, Takahashi K, Takase T, Yamamoto C, et al. (2019) Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. Endocr J 66: 995\u20131000.","DOI":"10.1507\/endocrj.EJ19-0136"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, et al. (2020) Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev e3413.","DOI":"10.1002\/dmrr.3413"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Maegawa H, Tobe K, Tabuchi H, Nakamura I (2016) Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opin Pharmacother 17: 1985\u20131994.","DOI":"10.1080\/14656566.2016.1217994"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tabuchi H, Maegawa H, Tobe K, Nakamura I, Uno S (2019) Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results). Endocr J 66: 31\u201341.","DOI":"10.1507\/endocrj.EJ18-0217"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, et al. (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.","DOI":"10.1186\/1471-230X-6-33"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Nakamura I, Maegawa H, Tobe K, Uno S (2021) Real-world evidence for long-term safety and effectiveness of ipragliflozin in japanese patients with type 2 diabetes mellitus: final results of a 3-year post-marketing surveillance study (STELLA-LONG TERM). Expert Opin Pharmacother 22: 373\u2013387.","DOI":"10.1080\/14656566.2020.1817388"},{"key":"26","unstructured":"26 Nakamura I, Tobe K, Maegawa H, Uno S (2019) Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus: 24-month interim results of the STELLA-LONG TERM post-marketing surveillance study. Jpn Pharmacol Ther 47: 1765\u20131789 (In Japanese)."},{"key":"27","unstructured":"27 Lowe D, Sanvictores T, John S (2020) Alkaline phosphatase. In: StatPearls [Internet]. StatPearls Publishing LLC, Copyright<sup>\u00a9<\/sup> 2020, Treasure Island (FL):"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Bando Y, Ogawa A, Ishikura K, Kanehara H, Hisada A, et al. (2017) The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int 8: 218\u2013227.","DOI":"10.1007\/s13340-016-0302-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, et al. (2016) Effects of sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 diabetes: a chart-based analysis. J Clin Med Res 8: 237\u2013243.","DOI":"10.14740\/jocmr2467w"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30 Sattar N, Fitchett D, Hantel S, George JT, Zinman B (2018) Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial. Diabetologia 61: 2155\u20132163.","DOI":"10.1007\/s00125-018-4702-3"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, et al. (2018) Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 53: 140\u2013151.","DOI":"10.1007\/s00535-017-1364-8"},{"key":"32","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"32 Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, et al. (2017) Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled Trial. Diabetes Care 40: 1364\u20131372.","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, et al. (2018) Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars) 13: 402\u2013409.","DOI":"10.1515\/med-2018-0059"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, et al. (2019) Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res 49: 531\u2013539.","DOI":"10.1111\/hepr.13304"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, et al. (2019) Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21: 285\u2013292.","DOI":"10.1111\/dom.13520"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, et al. (2019) Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res 49: 64\u201371.","DOI":"10.1111\/hepr.13236"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Yamashima M, Miyaaki H, Miuma S, Shibata H, Ryu Sasaki R, et al. (2019) The long-term efficacy of sodium glucose co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease. Intern Med 58: 1987\u20131992.","DOI":"10.2169\/internalmedicine.2566-18"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, et al. (2020) SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Intern Med 59: 1931\u20131937.","DOI":"10.2169\/internalmedicine.4398-19"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/8\/68_EJ20-0765\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:41:06Z","timestamp":1630107666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/8\/68_EJ20-0765\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0765","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"EJ20-0765"}}